Immuno-oncology is a unique approach that uses the body’s immune system to fight cancer. These therapies activate an individual’s immune system, making it able to recognize cancer cells and destroy them.
- Advertising -
Immuno-oncology therapies provide long lasting anti-cancer benefits to patients who previously had very few treatment options available to them. These therapies work against a large number of cancer types.
- Advertising -
The technological advancements are helping the growth of immuno-oncology market. The biotechnology and pharmaceutical companies are striving to launch new and most effective therapies.
Browse The Report: www.orbisresearch.com/reports/inde…-forecast-to-2022
According to the report “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) – Global Forecast to 2022”, the global immuno-oncology market is anticipated to cross US$ 100 Billion by 2022. The report provides a detailed analysis of the global immuno-oncology market.
The report also provides the current and forecasted market for immuno-oncology.
Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immuno-oncology market.
Moreover, the report provides the sales of major marketed immuno-oncology drugs.
The global immuno-oncology market has been segmented on the basis of type of product into monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme pro-drug therapy and radio immunotherapy).
The report also sheds light on the geographic segmentation of the global immuno-oncology market. In 2016, North America was estimated to account for the largest share.
Presence of major players, increased awareness and better distribution mechanisms are some of the prominent factors that have led to North America being the market leader.
On the basis of type of cancer, the immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.
A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immuno-oncology programs at various stages of clinical development.
In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.
The later part of the report discusses some of the prominent players in the global immuno-oncology market. Market share analysis of major players is also provided in the report.
Furthermore, a brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immuno-oncology is an important and rapidly emerging field.
This report will prove as a complete source of knowledge and analysis for clients and potential investors.
Major Points From The Table Of Contents:
Global Immuno-Oncology Market Outlook 2022
Global Immuno-Oncology Market, by Product Class
Global Immuno-Oncology Market, By Major Indications
Global Immuno-Oncology Market, By Geography
Trends & Developments
Strategic Collaborations & Alliances in the Immuno-Oncology Industry
Pipeline Analysis of Immuno-Oncology
Key Players Analysis
List Of Tables:
Table 4-1: Immuno-Oncology – Late Stage Research Pipeline
Table 4-2: US & Europe – Major Drug Patent Expiry in Immuno-Oncology Market
Table 6-1: Ongoing Trials for Rituxan
Table 6-2: Ongoing Trials for Avastin
Table 6-3: Ongoing Trials for Herceptin
Table 6-4: Ongoing Trials for ADCETRIS
Table 6-5: Ongoing Trials for Kadcyla
Table 6-6: Ongoing Trials for Blincyto
Table 6-7: Ongoing Trials for Other Monoclonal Antibodies
Table 6-8: Ongoing Trials for Provenge
Table 6-9: Ongoing Trials for Yervoy
Table 6-10: Ongoing Trials for Opdivo
Category: Market Research Publishers and RetailersCompany profile: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have a vast database of reports from the leading publishers and authors across the gl obe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their need, and we produce the perfect requi ...
For more information: